Ted Lamson

Ted Lamson, Ph.D. is Co-Founder and Chief Technical Officer of NeoTract, Inc., a wholly owned subsidiary of Teleflex, Inc. Ted is a primary inventor of the UroLift system for BPH and served as President and CEO of NeoTract for the first 4 years of the company and sat on its board of directors for the company's entire history. He now oversees reimbursement and health policy, clinical affairs and medical affairs under Teleflex Interventional Urology. Ted sits on the board of directors for Eximis Surgical and advises several other small medical device companies. He has over 25 years experience in the medical device industry in multiple fields and holds over 70 patents, many of which represent current commercial medical products. Ted has played a leadership role in other successful ventures, such as Vice President R&D for TransVascular, sold to Medtronic, co-inventor for Acclarent, sold to J&J, and Strategic Advisor to the ExploraMed incubator, which has launched several medical device companies including NeoTract, Inc. In addition to his deep start-up experience Ted has served as Vice President in the Vascular division of Medtronic and Section Manager within the prior-owned Schneider division of Pfizer. Ted held the position of Design Engineer for the Artificial Heart Program at Penn State University where he earned a MS and PhD in Biomedical Engineering. In 2011, Ted was awarded the Outstanding Engineering Alumnus award for Penn State, where he now serves on the curriculum advisory committee to the Biomedical Engineering department. Ted also holds a BS in Chemical Engineering from Rensselaer Polytechnic Institute.